A Phase 2b Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)

Brief description of study

The purpose of this study is to learn about the safety and effectiveness of a new experimental drug called MORF-057, in people with moderately to severely active ulcerative colitis. MORF-057 is also called the study drug in this document. This study will also look at the way the body absorbs, distributes, and gets rid of the study drug (called pharmacokinetics, or PK) and the way the study drug affects the body (called pharmacodynamics, or PD). The study drug is experimental. MORF-057 is not approved for commercial use because it is still being researched and a marketing application has not been approved by any health agency such as the U.S. Food and Drug Administration. MORF-057 is approved for use in this research study only for the purposes of gathering information.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.